Felix Biotechnology
Felix Biotechnology is a YC Winter 2020 (W20) company. Based in San Francisco, CA, USA. Team of 6.
About Felix Biotechnology
Summary
Felix Biotechnology builds a digital platform for designing viral therapies from end to end, targeting antimicrobial resistance. The platform lets researchers engineer bacteriophages programmatically, replacing the manual, trial-and-error wet-lab work traditionally required to develop phage-based treatments against drug-resistant bacterial infections.
From the Y Combinator listing
We’re creating programmable therapies
We are building the first end-to-end digital viral design platform to protect the world against the coming threat of antimicrobial resistance.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- San Francisco, CA, USA
- 6
- Inactive
- Early
Founders (3)
- Paul Turner
- Robert McBride
- Vivek Mutalik
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works